Assessing Unsupervised Exercise in Interstitial Lung Disease
Patients with interstitial lung diseases (ILDs), including lymphangioleiomyomatosis (LAM), have unique risks for adverse health events during exercise training outside of a medically supervised setting.
New Automated Method to Segment and Measure Lymphangioleiomyomatosis Lung Cysts in CT Images
This study addresses the cystic lung destruction in Lymphangioleiomyomatosis (LAM). Because LAM may progress over many years, doctors may use pulmonary function tests, exercise tests,
I Am a LAM Patient and Oxygen Advocate. Here’s Why Congress Needs to Pass the SOAR Bill.
Bev Jackson is one of the leading LAM community advocates for passing SOAR (Supplemental Oxygen Access Reform) legislation. Her interview has been edited for length
A Note From Pat Gentile
Greetings! How lucky am I that I get to work with the LAM community again?! Throughout my long professional career, I have never encountered a more
The Latest in LAM Science: Q & A with Kathryn Wikenheiser-Brokamp, PhD
Dr. Wikenheiser-Brokamp of Cincinnati Children’s Hospital Medical Center was awarded an Established Investigator Award in 2022 for her project titled: Identifying Cell-Cell Signaling Driving Pulmonary
A Potential Biomarker and Therapeutic Target for LAM
One of the greatest challenges in caring for patients with lymphangioleiomyomatosis (LAM) is to find better ways to track disease progression, either off or on
Take Action on Oxygen Reform: Call Your Senators and Representatives.
PHONE CALLS TO CONGRESS NEEDED The LAM community has an opportunity to advocate for improved oxygen therapy through a simple phone call to their congressional
New study explores the relationship between mTOR activation and pulmonary hypertension
Lymphangioleiomyomatosis (LAM) is a complex lung disease characterized by cyst formation due to mutations in the TSC1/2 genes, leading to the overactivation of a molecular
Specialized Protein TFEB May be Key to Understanding LAM
Tuberous Sclerosis Complex (TSC) is a genetic disorder caused by mutations in the TSC1 or TSC2 gene, leading to the hyperactivation of the mechanistic target
Dr. Lyndsay Hoy Appointed Chief Mission Officer of The LAM Foundation
The Board of Directors is pleased and excited to announce the appointment of Dr. Lyndsay Hoy as the inaugural Chief Mission Officer (CMO) of The
LAM Patient Research Priorities Survey Now Open
Dear LAM Community Members, The LAM Foundation prioritizes supporting LAM scientific research, funding a wide range of projects and initiatives. To maximize impact for LAM
Study suggests LAM is more prevalent than previously thought
“Rare diseases are often disregarded given their rarity. Most are underdiagnosed. The minute you tell clinicians that this is actually four to five times more